C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building.
A few takeaways stood out:
Clinical progress is accelerating across Parkinson’s disease, diabetes, retinal disorders, and other regenerative medicine programs.
iPSC-based therapies continue to gain momentum, with a growing focus on scalable, GMP-ready manufacturing.
Manufacturing excellence is now a major differentiator, with automation, closed systems, and robust quality control taking center stage.
AI and advanced analyticsare accelerating cell therapy development and process optimization.
The future of cell and gene therapy will be driven not only by breakthrough science, but by the ability to manufacture safe, consistent, and scalable therapies that reach patients worldwide.
That’s exactly the challenge C3i is built to solve. If your program has development or manufacturing needs on the horizon, contact our team to explore how we can support your path from bench to patient.
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
Montreal CDMO expands beyond cell therapy manufacturing with companion diagnostics, therapeutic monitoring, and integrated patient support programs. What if every patient received a therapy tailored to their unique biology? That question, aligned with the aspirational promise of precision medicine, is now at the heart of what C3i does. The Montreal-based contract development and manufacturing organization […]
